IOVANCE BIOTHERAPEUTICS, INC. IOVA Balance Sheet

Iovance biotherapeutics, inc. (IOVA)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Current Assets
Cash and cash equivalents
52,540	13,969	38,889	76,912	54,093	82,152	80,738	246,017	297,082	145,373	163,380	114,285	107,099	106,717	92,895	101,222	8,943	33,587	10,210	12,556	111,280	44,909	17,189	18,440	17,943	19,672	129	569	-	0	0	15	0	510	910	268	1,292
Short-term investments
193,100	293,112	322,985	327,241	385,925	386,371	179,262	30,082	-	0	0	14,732	40,098	59,753	86,387	70,602	60,251	70,113	79,374	92,302	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,744	29,972	-	20,562	7,476	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
10,729	9,412	5,433	6,785	4,735	6,851	5,863	3,682	5,644	3,917	7,995	6,417	5,396	3,042	1,274	782	193	277	245	378	128	66	15	9	10	173	5	5	5	5	5	8	34	9	-	-	-
Advances to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	50	-
Deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	7	5
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41	69	114	-	3	4	3	2	-	-	-	4	0	0	3
Total Current Assets
256,381	316,493	367,307	410,938	444,753	475,374	265,863	279,781	302,726	149,290	171,375	135,434	152,593	169,512	180,556	192,350	99,359	103,977	110,391	112,714	111,409	44,975	17,230	18,519	18,067	19,845	138	578	8	7	5	24	34	524	3,298	326	1,300
Property and equipment, net
13,607	8,536	5,856	4,472	3,504	2,683	2,640	2,706	2,247	2,450	2,595	2,578	2,796	2,374	1,769	1,192	1,409	1,676	1,833	2,025	2,128	1,532	170	15	14	27	29	19	20	22	23	25	26	28	18	16	0
Operating lease right-of-use assets
9,305	10,695	13,738	11,719	9,957	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
5,525	5,450	5,450	5,450	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,320	-	-
Long-term assets
3,480	3,481	3,395	3,345	3,288	2,764	2,331	2,264	2,275	3,633	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intellectual property licenses, net of accumulated amortization of $217,408 and $217,408
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	105	123	160
Rent Deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	16	16	16	16	-	0
Total Assets
288,298	344,655	395,746	435,924	461,502	480,821	270,834	284,751	307,248	155,373	173,970	138,012	155,389	171,886	182,325	193,542	100,768	105,653	112,224	114,739	113,537	46,507	17,416	18,535	18,082	19,873	168	597	28	29	28	65	76	568	3,438	466	1,460
Current Liabilities
Bank overdraft
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	-	-	-	-
Accounts payable
10,614	15,567	9,921	12,782	7,589	2,739	6,014	5,196	6,576	1,232	2,905	3,695	2,174	863	228	725	1,054	958	1,161	1,156	1,107	1,248	573	440	286	412	1,550	1,480	1,291	1,098	841	609	504	190	206	130	30
Accrued expenses
22,500	16,265	16,322	13,570	8,489	11,659	10,660	8,986	8,114	8,363	5,624	5,165	3,329	4,105	2,966	3,881	690	672	1,608	623	717	328	476	715	823	1,518	1,958	1,888	1,863	1,740	1,011	502	279	67	31	-	0
Operating lease liabilities - current
6,431	7,252	8,370	7,484	6,059	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued payable to officers and former directors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86	-	86	85	85	86	208	-	-	338	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses - National Institutes of Health
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	616	616	866	-	-	-	-
7% Senior secured convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	5,000	5,000	5,000	5,000	5,000	5,000	2,598	-	0
12% secured promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,231	1,231	1,231	1,216	-	0	-	-	-
September 2012 secured promissory note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	250	250	250	-	-	0	-	-	-
18% secured convertible promissory note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300	-	-	-	-	-	-	-	-
Accrued interest and penalty
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,370	2,029	-	-	-	153	-	-	-
Derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,659	8,740	10,667	7,937	6,292	1,739	792
Total Current Liabilities
39,545	39,084	34,613	33,836	22,137	14,398	16,674	14,182	14,690	9,595	8,529	8,860	5,503	4,968	3,194	4,606	1,830	1,630	2,855	1,866	1,910	1,662	1,258	1,156	1,109	2,269	3,509	3,369	12,306	11,348	16,610	16,683	17,335	13,349	9,129	1,870	822
Non-Current Liabilities
Operating lease liabilities - noncurrent
3,088	4,248	6,017	4,613	4,380	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
2,352	2,352	53	53	53	230	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	297	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities
5,440	6,600	6,070	4,666	4,433	230	-	-	-	297	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities
44,985	45,684	40,683	38,502	26,570	14,628	-	-	-	9,892	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation payable in shares of stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	167	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and contingencies (Notes 8 and 9)
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	-	0	0	-	-	0
Stockholders' Equity
Preferred stock, Value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	-	-	0	-	-	-	-	-	-	-
Common stock, $0.000041666 par value; 300,000,000 shares authorized, 126,823,156 and 126,411,808 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively
5	5	5	5	5	5	4	4	3	3	3	3	3	3	3	3	2	2	2	1	1	2	1	1	0	0	0	0	0	0	3	3	3	3	3	3	3
Common stock to be issued, 303,125 shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	245	245	245	-	245	245	245	245	245	245	245	245	245	245	245	245	497	497	-	0	-	-	-
Accumulated other comprehensive income
912	220	861,859	854,596	138	-42	-120	-3	-	0	0	0	2	29	163	78	68	48	38	21	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
882,599	869,354	239	372	844,789	838,984	594,455	576,917	568,243	394,651	388,756	330,318	327,673	323,994	320,140	311,268	209,729	208,195	204,929	200,832	193,239	121,160	87,607	86,029	83,346	81,884	40,582	31,742	19,206	19,119	17,067	16,357	15,887	14,592	13,330	11,799	2,317
Common stock subscribed for, 400,000 shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400	400	-	-	-	-	-	-	-	-	-
Accumulated deficit
-640,207	-570,612	-507,044	-457,557	-410,006	-372,760	-340,185	-306,355	-275,695	-249,180	-223,326	-201,177	-177,800	-157,116	-141,428	-122,669	-111,106	-104,222	-95,845	-88,227	-81,859	-76,562	-71,695	-68,896	-66,786	-64,527	-44,569	-35,159	-31,730	-30,684	-34,150	-33,476	-33,149	-27,376	-19,024	-13,206	-1,682
Total Stockholders' Equity
243,313	298,971	355,063	397,422	434,932	466,193	254,160	270,569	292,558	145,481	165,441	129,152	149,886	166,918	179,131	188,936	98,938	104,023	109,369	112,873	111,626	44,845	16,158	17,378	16,806	17,603	-3,340	-2,771	-12,278	-11,319	-16,581	-16,618	-17,258	-12,780	-5,690	-1,403	638
Total Liabilities and Stockholders' Equity
288,298	344,655	395,746	435,924	461,502	480,821	270,834	284,751	307,248	155,373	173,970	138,012	155,389	171,886	182,325	193,542	100,768	105,653	112,224	114,739	113,537	46,507	17,416	18,535	18,082	19,873	168	597	28	29	28	65	76	568	3,438	466	1,460
Series A Convertible Preferred Stock
Preferred stock, Value
-	-	-	-	0	-	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series B Convertible Preferred Stock
Preferred stock, Value
4	4	4	6	6	6	6	6	7	7	8	8	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders' Equity
4	4	4	6	6	6	-	-	-	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series A Convertible Preferred stock [Member]
Total Stockholders' Equity
-	-	-	-	0	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-